Vobarilizumab

From WikiProjectMed
Jump to navigation Jump to search
Vobarilizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetIL6R
Clinical data
Other namesALX0061
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1118H1757N315O364S8
Molar mass25691.68 g·mol−1

Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2][3]

This drug was developed by Ablynx NV.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
  3. ^ Hassan N, Choy E (September 2020). "Interleukin-6 inhibitors". In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis. Oxford University Press. p. 394. doi:10.1093/med/9780198831433.003.0032. ISBN 978-0-19-256710-9.